John Hall, PhD

Associate Director, Genetic Medicines Research at Dyne Therapeutics

Speaker

Dr. John Hall is currently Associate Director, Genetic Medicines Research at Dyne Therapeutics, where the team is advancing the FORCE™ platform for the treatment of neuromuscular disorders. Prior to joining Dyne, John held scientific roles at Capricor Therapeutics and California Institute of Technology where he was responsible for the development of exosome-based therapeutic delivery for Duchenne muscular dystrophy and multiplex HCR in situ technology. He earned a B.S. in Biology from the University of Tulsa and Ph.D. in Molecular, Cellular & Developmental Biology from the University of Colorado at Boulder. John completed postdoctoral fellowships at the University of Washington Medical School.